Ana Luisa Rodrigues Toste de Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Luisa Rodrigues Toste de Carvalho has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ana Aires
Neurology, Unidade Local de Saude de Sao Joao, Porto, Portugal
1 shared publicationAna Pastor
Internal Medicine, Unidade Local de Saude de Sao Joao, Porto, Portugal
1 shared publicationAnne Moscona
Department of Pediatrics, Columbia University Medical Center, New York, USA
1 shared publicationCarlos Grijó
Internal Medicine, Unidade Local de Saude de Sao Joao, Porto, Portugal
1 shared publication- Caroline Borges-Pereira
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal
1 shared publication - Catarina Barbosa-Matos
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal
1 shared publication
Latest Publications
- 13 February 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (6) , 599-603
Serotonin syndrome presenting as severe reversible cerebral vasoconstriction syndrome
Serotonin syndrome is a life-threatening adverse drug reaction caused by excessive serotonergic activity from therapeutic use, overdose or drug interactions. Its recognition is challenging, as manifestations range from subtle to severe and fatal. Key diagnostic features are autonomic dysfunction, motor hyperactivity and exaggerated reflexes, including clonus. We report a young woman with severe serotonin syndrome due to serotonergic polypharmacy who developed reversible cerebral vasoconstriction syndrome and overlapping posterior reversible encephalopathy syndrome. The diagnosis was initially delayed because attention had focused on her prominent vascular features with severe focal neurological deficits rather than the underlying toxidrome. We diagnosed serotonin syndrome as she developed more characteristic features. This case highlights the importance of considering serotonin syndrome in patients receiving serotonergic medications who develop motor findings, autonomic dysfunction or unexplained neurological deterioration.
- 13 February 2026
- Published by BMJ in Practical Neurology
- Vol. 26 (6) , 599-603
Serotonin syndrome presenting as severe reversible cerebral vasoconstriction syndrome
Serotonin syndrome is a life-threatening adverse drug reaction caused by excessive serotonergic activity from therapeutic use, overdose or drug interactions. Its recognition is challenging, as manifestations range from subtle to severe and fatal. Key diagnostic features are autonomic dysfunction, motor hyperactivity and exaggerated reflexes, including clonus. We report a young woman with severe serotonin syndrome due to serotonergic polypharmacy who developed reversible cerebral vasoconstriction syndrome and overlapping posterior reversible encephalopathy syndrome. The diagnosis was initially delayed because attention had focused on her prominent vascular features with severe focal neurological deficits rather than the underlying toxidrome. We diagnosed serotonin syndrome as she developed more characteristic features. This case highlights the importance of considering serotonin syndrome in patients receiving serotonergic medications who develop motor findings, autonomic dysfunction or unexplained neurological deterioration.
- Open Access
- 20 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1279
Glycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that currently lacks effective clinical treatments. Evidence highlights the potential role of glycogen synthase kinase-3 (GSK-3) inhibition in mitigating severe inflammation. The inhibition of GSK-3α/β by CHIR99021 promoted fetal lung progenitor proliferation and maturation of alveolar epithelial cells (AECs). The precise impact of CHIR99021 in lung repair and regeneration during acute lung injury (ALI) remains unexplored. This study intends to elucidate the influence of CHIR99021 on AEC behaviour during the peak of the inflammatory phase of ALI and, after its attenuation, during the repair and regeneration stage. Furthermore, a long-term evaluation was conducted post CHIR99021 treatment at a late phase of the disease. Our results disclosed the role of GSK-3α/β inhibition in promoting AECI and AECII proliferation. Later administration of CHIR99021 during ALI progression contributed to the transdifferentiation of AECII into AECI and an AECI/AECII increase, suggesting its contribution to the renewal of the alveolar epithelial population and lung regeneration. This effect was confirmed to be maintained histologically in the long term. These findings underscore the potential of targeted therapies that modulate GSK-3α/β inhibition, offering innovative approaches for managing acute lung diseases, mostly in later stages where no treatment is available.
- 20 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1279
Open AccessGlycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that currently lacks effective clinical treatments. Evidence highlights the potential role of glycogen synthase kinase-3 (GSK-3) inhibition in mitigating severe inflammation. The inhibition of GSK-3α/β by CHIR99021 promoted fetal lung progenitor proliferation and maturation of alveolar epithelial cells (AECs). The precise impact of CHIR99021 in lung repair and regeneration during acute lung injury (ALI) remains unexplored. This study intends to elucidate the influence of CHIR99021 on AEC behaviour during the peak of the inflammatory phase of ALI and, after its attenuation, during the repair and regeneration stage. Furthermore, a long-term evaluation was conducted post CHIR99021 treatment at a late phase of the disease. Our results disclosed the role of GSK-3α/β inhibition in promoting AECI and AECII proliferation. Later administration of CHIR99021 during ALI progression contributed to the transdifferentiation of AECII into AECI and an AECI/AECII increase, suggesting its contribution to the renewal of the alveolar epithelial population and lung regeneration. This effect was confirmed to be maintained histologically in the long term. These findings underscore the potential of targeted therapies that modulate GSK-3α/β inhibition, offering innovative approaches for managing acute lung diseases, mostly in later stages where no treatment is available.
- 1 March 2021
- Published by Springer Nature in Nature Protocols
- Vol. 16 (4) , 1802-1829
The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell–derived lung progenitors in 3D
Lung and airway epithelial cells generated in vitro from human pluripotent stem cells (hPSCs) have applications in regenerative medicine, modeling of lung disease, drug screening and studies of human lung development. Here, we describe a strategy for directed differentiation of hPSCs into mature lung and airway epithelial cells obtained through maturation of NKX2.1+ hPSC-derived lung progenitors in a 3D matrix of collagen I in the absence of glycogen synthase kinase 3 inhibition. This protocol is an extension of our previously published protocol on the directed differentiation of lung and airway epithelium from hPSCs that modifies the technique and offers additional applications. This protocol is conducted in defined media conditions, has a duration of 50–80 d, does not require reporter lines and results in cultures containing mature alveolar type II and I cells as well as airway basal, ciliated, club and neuroendocrine cells. We also present a flow cytometry strategy to assess maturation in the cultures. Several of these populations, including mature NGFR+ basal cells, can be prospectively isolated by cell sorting and expanded for further investigation.
- 1 March 2021
- Published by Springer Nature in Nature Protocols
- Vol. 16 (4) , 1802-1829
The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell–derived lung progenitors in 3D
Lung and airway epithelial cells generated in vitro from human pluripotent stem cells (hPSCs) have applications in regenerative medicine, modeling of lung disease, drug screening and studies of human lung development. Here, we describe a strategy for directed differentiation of hPSCs into mature lung and airway epithelial cells obtained through maturation of NKX2.1+ hPSC-derived lung progenitors in a 3D matrix of collagen I in the absence of glycogen synthase kinase 3 inhibition. This protocol is an extension of our previously published protocol on the directed differentiation of lung and airway epithelium from hPSCs that modifies the technique and offers additional applications. This protocol is conducted in defined media conditions, has a duration of 50–80 d, does not require reporter lines and results in cultures containing mature alveolar type II and I cells as well as airway basal, ciliated, club and neuroendocrine cells. We also present a flow cytometry strategy to assess maturation in the cultures. Several of these populations, including mature NGFR+ basal cells, can be prospectively isolated by cell sorting and expanded for further investigation.